<DOC>
	<DOCNO>NCT01756898</DOCNO>
	<brief_summary>The purpose research study gather scientific information effectiveness study drug , ASB17061 capsule , compare placebo adult subject atopic dermatitis .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety Pharmacokinetics ASB17061 Capsules Adult Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Adult subject age 18 65 year A diagnosis atopic dermatitis ( AD ) An IGA score 2 high AD affect least 5 % total Body Surface Area ( BSA ) Other active AD , good health medical condition may jeopardize safety subject impact validity study result Subjects must practice acceptable birth control method Taking systemic immunosuppressive therapy within 3 month prior screen systemic ( cortico ) steroid therapy within 4 week prior screen Use phototherapy tan bed within 6 week screen Presence clinically significant disorder involve gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease condition , jeopardize safety subject impact validity study result Female subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>eczema</keyword>
</DOC>